BioCryst Pharmaceuticals Inc.

14.37-0.3900-2.64%Vol 3.25M1Y Perf -5.26%
Aug 11th, 2022 16:00 DELAYED
BID14.24 ASK14.90
Open14.79 Previous Close14.76
Pre-Market- After-Market14.35
 - -  -0.02 -0.14%
Target Price
17.55 
Analyst Rating
Moderate Buy 2.09
Potential %
22.13 
Finscreener Ranking
★+     42.40
Insiders Trans % 3/6/12 mo.
-/-100/-75 
Value Ranking
★★     47.26
Insiders Value % 3/6/12 mo.
-/-100/-89 
Growth Ranking
★★     44.13
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-87 
Income Ranking
 —    -
Price Range Ratio 52W %
54.60 
Earnings Rating
Sell
Market Cap2.67B 
Earnings Date
4th Aug 2022
Alpha0.01 Standard Deviation0.22
Beta2.29 

Today's Price Range

14.2214.97

52W Range

7.6119.99

5 Year PE Ratio Range

-6.70-9.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
2.28%
1 Month
27.85%
3 Months
82.13%
6 Months
-19.22%
1 Year
-5.26%
3 Years
442.26%
5 Years
217.22%
10 Years
257.46%

TickerPriceChg.Chg.%
BCRX14.37-0.3900-2.64
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
99.20
-64.50
-64.00
-406.70
-87.77
RevenueValueIndustryS&P 500US Markets
138.08M
0.74
67.93
32.26
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.36-0.3211.11
Q01 2022-0.39-0.40-2.56
Q04 2021-0.31-0.40-29.03
Q03 2021-0.30-0.33-10.00
Q02 2021-0.22-0.24-9.09
Q01 2021-0.26-0.36-38.46
Q04 2020-0.25-0.34-36.00
Q03 2020-0.25-0.26-4.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.360.00-
9/2022 QR-0.332.94Positive
12/2022 FY-1.341.47Positive
12/2023 FY-0.6024.05Positive
Next Report Date-
Estimated EPS Next Report-0.36
Estimates Count6
EPS Growth Next 5 Years %4.50
Volume Overview
Volume3.25M
Shares Outstanding185.95K
Shares Float165.42M
Trades Count27.36K
Dollar Volume47.08M
Avg. Volume3.93M
Avg. Weekly Volume5.58M
Avg. Monthly Volume2.99M
Avg. Quarterly Volume3.23M

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) stock closed at 14.37 per share at the end of the most recent trading day (a -2.64% change compared to the prior day closing price) with a volume of 3.25M shares and market capitalization of 2.67B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 140 people. BioCryst Pharmaceuticals Inc. CEO is Jon P. Stonehouse.

The one-year performance of BioCryst Pharmaceuticals Inc. stock is -5.26%, while year-to-date (YTD) performance is 3.75%. BCRX stock has a five-year performance of 217.22%. Its 52-week range is between 7.61 and 19.99, which gives BCRX stock a 52-week price range ratio of 54.60%

BioCryst Pharmaceuticals Inc. currently has a PE ratio of -10.90, a price-to-book (PB) ratio of 56.59, a price-to-sale (PS) ratio of 15.27, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.72%, a ROC of -96.99% and a ROE of 165.07%. The company’s profit margin is -87.77%, its EBITDA margin is -64.00%, and its revenue ttm is $138.08 Million , which makes it $0.74 revenue per share.

Of the last four earnings reports from BioCryst Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.36 for the next earnings report. BioCryst Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for BioCryst Pharmaceuticals Inc. is Moderate Buy (2.09), with a target price of $17.55, which is +22.13% compared to the current price. The earnings rating for BioCryst Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

BioCryst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

BioCryst Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.46, ATR14 : 0.88, CCI20 : 127.94, Chaikin Money Flow : 0.12, MACD : 0.91, Money Flow Index : 74.45, ROC : 33.18, RSI : 58.72, STOCH (14,3) : 78.23, STOCH RSI : 0.87, UO : 59.62, Williams %R : -21.77), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of BioCryst Pharmaceuticals Inc. in the last 12-months were: Anthony Doyle (Buy at a value of $440 020), George B. Abercrombie (Option Excercise at a value of $169 060), George B. Abercrombie (Sold 94 000 shares of value $1 401 010 ), Helen M. Thackray (Sold 7 600 shares of value $123 120 ), Jon P. Stonehouse (Option Excercise at a value of $870 320), Jon P. Stonehouse (Sold 184 000 shares of value $2 767 360 ), Kenneth B. Lee (Option Excercise at a value of $48 300), Kenneth B. Lee (Sold 6 000 shares of value $92 100 ), Michael L. Jones (Option Excercise at a value of $10 879), Michael L. Jones (Sold 2 300 shares of value $39 560 ), Nancy J. Hutson (Option Excercise at a value of $122 250), Nancy J. Hutson (Sold 105 000 shares of value $1 617 000 ), Vincent J. Milano (Buy at a value of $91 425), William P. Sheridan (Option Excercise at a value of $477 532), William P. Sheridan (Sold 161 139 shares of value $2 719 493 ), Yarlagadda S. Babu (Option Excercise at a value of $293 260), Yarlagadda S. Babu (Sold 50 100 shares of value $710 420 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (45.45 %)
6 (60.00 %)
7 (63.64 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
6 (54.55 %)
4 (40.00 %)
4 (36.36 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.09
Moderate Buy
1.80
Moderate Buy
1.73

BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

CEO: Jon P. Stonehouse

Telephone: +1 919 859-1302

Address: 4505 Emperor Boulevard, Durham 27703, NC, US

Number of employees: 140

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

67%33%

Bearish Bullish

64%36%

TipRanks News for BCRX

Thu, 04 Aug 2022 17:55 GMT Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Concert Pharma (CNCE)

- TipRanks. All rights reserved.

Tue, 02 Aug 2022 01:45 GMT Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), Edwards Lifesciences (EW) and Bausch + Lomb Corporation (BLCO)

- TipRanks. All rights reserved.

Sat, 09 Jul 2022 01:45 GMT Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD), BioCryst (BCRX) and Cigna (CI)

- TipRanks. All rights reserved.

Mon, 13 Jun 2022 03:57 GMT BioCryst (BCRX) Receives a Buy from Evercore ISI

- TipRanks. All rights reserved.

Wed, 08 Jun 2022 17:25 GMT Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Precision BioSciences (DTIL)

- TipRanks. All rights reserved.

Mon, 09 May 2022 18:43 GMT Has BioCryst Hit Bottom Looking for the Silver Lining

- TipRanks. All rights reserved.

Sat, 07 May 2022 01:15 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), BioCryst (BCRX) and McKesson (MCK)

- TipRanks. All rights reserved.

Thu, 05 May 2022 16:45 GMT Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), Concert Pharma (CNCE) and OrthoPediatrics (KIDS)

- TipRanks. All rights reserved.

Thu, 14 Apr 2022 18:35 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (BCRX), Artivion (AORT) and Longeveron (LGVN)

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 13:04 GMT Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and AbbVie (ABBV)

- TipRanks. All rights reserved.

Sat, 19 Mar 2022 01:45 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: BioCryst (BCRX) and BELLUS Health (BLU)

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 18:48 GMT BioCryst Stock at $21 a Share This Analyst Thinks Its Possible

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 10:45 GMT BioCryst (BCRX) Receives a Hold from Needham

- TipRanks. All rights reserved.

Tue, 11 Jan 2022 05:35 GMT Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Cellectis SA (CLLS)

- TipRanks. All rights reserved.

Sun, 09 Jan 2022 13:06 GMT Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), BioCryst (BCRX) and Intellia Therapeutics (NTLA)

- TipRanks. All rights reserved.

Fri, 07 Jan 2022 15:35 GMT BioCryst (BCRX) Gets a Buy Rating from JMP Securities

- TipRanks. All rights reserved.

News

Stocktwits